41 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels
U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results
U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday.
SAB Biotherapeutics Reports Phase 2 Virology Data Demonstrating SAB-185 Met Criteria For Advancement To Phase 3 In NIH ACTIV-2 Trial For Treatment Of COVID-19; Co. Reports ‘SAB-185 was safe and well-tolerated at both doses tested in Phase 2’
SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
FDA laboratory testing confirms SAB-185 neutralizes Omicron
and other variants of concern with in vitro pseudovirus model
SAB’s targeted, highly potent and fully-human polyclonal antibodies continue
to show broad
SAB Biotherapeutics’ Influenza Candidate Achieves Primary Goal In Mid-Stage Study
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza.
The Daily Biotech Pulse: Adcom Backs Merck’s Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours:
